AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06524232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Performance Incentives (PI)
Description: We will work closely with key stakeholders and the Steering Committee to co-design the PI strategy, refining the specific performance metrics to ensure that they align with other ongoing efforts in our partnering organizations. We plan to base the incentive on achieving a threshold target for the percentage of eligible adult patients screened for SUD, or the percentage improvement in screening, for quarters 1 and 2. For quarters 3 and 4, after practices have had time to implement and improve their processes for screening for SUD, the incentives will evolve to become a composite of (1) patients screened for SUD (the same as used in quarters 1 and 2) and (2) achieving a threshold target for the percentage of persons with SUD who received evidence-based interventions.
Study NCT06525064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health-E You app
Description: When clinics are in the intervention condition, all patients presenting for any reason will get a study weblink 24 hours before the visit; walk-ins will get a study link code in clinic. If the participants agree to participate and meet study criteria, the participants will get a survey link and then Health-E You content to complete before the visit. Previously enrolled males will not be enrolled again to maintain the research study's integrity. Thus, participants will only have one opportunity for administration to the Health-E You app.~Participants will be considered to have completed the Health-E You app if the participants answer all of the app's initial tailoring questions and receive recommendations for SRH topics to discuss with the clinician. As a technology-based intervention, no direct interactions with interventionists with participants are required.
Study NCT05630781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belsomra
Description: randomized, double-blind, placebo-controlled crossover design study: Participants will undergo a baseline scan followed by 2 acute drug administration scans where suvorexant or placebo is administered in a randomized manner where both the participant and study staff administering drug are blind. Following the second acute scan, participants will continue with the drug they received at Scan 2 for approximately 7 days. After the first chronic scan, participants will switch to the other drug for an additional \~7 days and then scanned a final time.
Study NCT05630781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belsomra
Description: randomized, double-blind, placebo-controlled crossover design study: Participants will undergo a baseline scan followed by 2 acute drug administration scans where suvorexant or placebo is administered in a randomized manner where both the participant and study staff administering drug are blind. Following the second acute scan, participants will continue with the drug they received at Scan 2 for approximately 7 days. After the first chronic scan, participants will switch to the other drug for an additional \~7 days and then scanned a final time.
Study NCT05630781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: comparator taken for \~10 days
Study NCT05150847 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oxygenation
Description: Oxygenation will be calculated as PaO2/ FiO2 ratio.Static compliance will be calculated as tidal volume divided driving pressure.The potential for lung recruitment will be assessed by means of the R/I ratio (10).
Study NCT05630781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: comparator taken for \~10 days
Study NCT05630781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Control Arm: Baseline visit with 2 fMRI scans pre- and post-20mg methylphenidate, 4 acute drug administration (6-14 days in randomized order: 1. Placebo + placebo; 2. 20mg suvorexant + Placebo; 3. Placebo + 40mg methylphenidate; 4. 20 mg suvorexant + 40mg methylphenidate max)
Study NCT05887531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Patients will be included in a prehabilitation program
Study NCT04956640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537982
Description: Oral
Study NCT04956640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous
Study NCT04956640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Intravenous
Study NCT04956640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Intravenous
Study NCT04956640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous
Study NCT05435937 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partnering for change (P4C-Swe)
Description: P4C focuses on the collaboration and a intersectional partnership between teachers and occupational therapists/special educators to create physical, social and learning environments that facilitate successful participation for all pupils. The intervention tiered model provides interventions in a school context in levels; class, group, and individual level to students with participation restrictions.~Dynamic Performance Analysis (DPA), which focuses on pupils' occupational performance, is used in P4C model to identify and analyze were and why pupils' occupational performance is breaking down in school-based occupations in the natural context, followed by collaboration and coaching between the occupational therapist and teacher in setting up goals, planning, implementing and monitoring intervention at the different intervention levels, to support participation.
Study NCT05435937 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual is provided by the Student health services that consists of a school doctor, school nurse, psychologist and counselor, and staff with special educational competence
Study NCT05811520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular stabilization exercises with conventional therapy
Description: The patient will sit on the knees in 90° flexion position, and a Swiss ball will be placed between the chest and stomach. From the side, the earlobe, acromion of scapula, and pelvis should made a straight line. Four general exercises will be included with 2 sets of 15 repetitions, holding for 10 sec
Study NCT05811520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic extension exercises with conventional therapy
Description: Thoracic extension exercises consist of three exercise protocols
Study NCT05203757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ArthroCT scan
Description: Conventional CT arthrogram as routine care
Study NCT05203757 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CBCT
Description: Cone Beam CT scan.
Study NCT04956640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous
Study NCT06006117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab + Lenalidomide
Description: * Mosunetuzumab will be administered SC (21 days first cycle, then 28 days next cycles)~  * C1 (21-days cycle): step-up dosing schedule 5 mg Day 1, 45 mg on Day 8 and 45 mg Day 15~ * C2 to C12: 45 mg D1 28-days cycles~* Lenalidomide PO 20 mg/day from Day 1 to Day 21 from cycles C2 to C6 (cycles of 28 days)
Study NCT06006117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: - Rituximab + Lenalidomide (28-days cycles
Description: * Lenalidomide PO 20 mg/day, D1-21 from cycle 1 to cycle 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12
Study NCT06006117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: - Rituximab + Bendamustine (28-days cycles)
Description: * Bendamustine IV 70 or 90 mg/m² (according to the investigator's judgment) D1 and D2/28 days x 6 cycles 28 days cycles). For patients in complete response (CR) at 3 cycles, Bendamustine and Rituximab could be stopped after 4 cycles at investigator discretion~* Rituximab\* 375 mg/m2 intravenously at cycle 1 Day 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6\*\* (28-days cycles) and then at D1 of three additional 56-days cycles (C7 to C9). \*\*For patients in complete response (CR) at 3 cycles, if Bendamustine is stopped, then Rituximab should also be omitted for C5 and C6.
Study NCT06006117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: - Rituximab + CHOP (21-days cycles)
Description: * CHOP, IV standard dose from cycle 1 to 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2 to 6 (21-days cycles), and then at D1 of three additional 56-days cycles (C7 to C9)
Study NCT05113433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session.
Study NCT06464016 — intervention group
Intervention type: DEVICE
Intervention: Ventricular Assist Device with Berlin Heart EXCOR
Description: The Berlin Heart® EXCOR is a type of artificial heart pump that pulls blood from the ventricle and then sends that blood to the aorta or pulmonary trunc, thereby taking away extra work from the native heart. The device, which comes in several sizes, is not totally implanted inside the body.
Study NCT04986930 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT+mFOLFIRINOX
Description: Stereotactic body radiotherapy: 3500 cGy (5 fractions) mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
Study NCT04986930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFIRINOX
Description: mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
Study NCT05432986 — intervention group
Intervention type: DEVICE
Intervention: Thermal Anisotropy Measurement Device
Description: A wireless device for non-invasively assessing CSF shunt flow.
Study NCT05581953 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Omnivorous
Description: Pork-added plant-forward diet
Study NCT05581953 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No meat
Description: Plant-forward no meat
Study NCT05113433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standing frame.
Description: muscle strengthening i.e. isometrics of lower limb muscles. 5 sets/rep and 2 sets/ session.~stretching of lower limb muscles . 5sets/rep and 2 sets/session. sanding on standing frame for different time period according to group with upper limb activities lie box and blocks , cones and theraputty .
Study NCT05357066 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide gas for inhalation
Description: Administration of inhaled 50% nitrous oxide in oxygen (FiO2 0.5) will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Study NCT05357066 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of the placebo (oxygen-air mixture \[FiO2 ≈0.3\]), will be under the direct supervision of a licensed practitioner who is experienced in the use and administration of the study drug, and is familiar with the indications, effects, dosages, methods, and frequency and duration of administration, and with the hazards, contraindications, and side effects and the precautions to be taken (MD, or CRNA); with study patient monitoring of pulse oximetry, heart rate, respiratory, non-invasive blood pressure, and end-tidal carbon dioxide.
Study NCT04775862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: investigator choice re-challenge with anti EGFR Rx
Description: Upon second progression, patients will be enrolled into the study as per inclusion criteria and consent, and a cfDNA blood test will be drawn, and RAS status will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).
Study NCT04775862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: investigator choice re-challenge with anti EGFR Rx
Description: Upon second progression, patients will be enrolled into the study as per inclusion criteria and consent, and a cfDNA blood test will be drawn, and RAS status will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).
Study NCT05462444 — intervention group
Intervention type: OTHER
Intervention: Skin prick test
Description: Skin prick test with a standard pallete of inhalational and nutritional allergens
Study NCT05556135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: level of serun adiponectin
Description: estimation of level of serum adiponectin in NAFLD for early detection of renal impairement
Study NCT02839447 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic
Description: Diagnostic
Study NCT05465798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC 3x3
Description: Patients allocated to this arm will receive MC 3x3, an oral supplement containing 25mg of 1,3 beta-Glucans of fungal origin (Trichoderma sp.) daily for up to three consecutive days.
Study NCT05465798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients allocated to this arm will receive a matching placebo similar to MC 3x3 pills used in the intervention arm. Placebos will be delivered orally every day for up to three consecutive days.
Study NCT03418649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone 50 Mg Tab
Description: 50 mg PO per day for 10 days
Study NCT03418649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: PO once daily for 10 days
Study NCT05250635 — intervention group
Intervention type: DEVICE
Intervention: electronic stethoscope
Description: It includes main machine and auscultation patch, which can stick on patient's body to collect and amplify breath sound.
Study NCT00904930 — intervention group
Intervention type: DEVICE
Intervention: Wire Composite Splint (Dentaflex 0.45 mm)
Description: Wire-Composite-Splint: Dentaflex 0.45 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow (IvoclarVivadent, Schaadn, Liechtenstein) to the teeth
Study NCT00904930 — intervention group
Intervention type: DEVICE
Intervention: Wire Composite Splint (Denture Strengtheners)
Description: Wire-Composite-Splint: Denture Strengtheners 0.8x1.8 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow to the teeth
Study NCT05109039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine
Description: Participants will consume 0.1g/kg body weight of creatine with 0.1g/kg body weight of maltodextrin for 42 consecutive days
Study NCT05109039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume 0.2g/kg body weight of maltodextrin for 42 consecutive days
Study NCT05693246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Description: At 10 minutes after endotracheal intubation, the Glycopyrrolate group was injected intravenously with 0.004mg/kg glycopyrrolate.
Study NCT05693246 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: At 10 minutes after endotracheal intubation, the Control group was intravenously injected with equal dose of normal saline.
Study NCT04473014 — intervention group
Intervention type: BEHAVIORAL
Intervention: Heat Pain Paradigm
Description: A standardized heat pain paradigm will be applied. Pain threshold will be determined with the self-controlled search method starting at 32°C, with a mouse-click-induced increase of 0.1°C per click. Pain tolerance is defined as the time in seconds elapsed from the onset of the pain stimulus to a participant's withdrawal from the stimulus. Participants will be instructed to continue with the task for as long as they can and to press a button if it becomes too uncomfortable or painful. Temperature will then return to baseline. To avoid physical injury, the measurement will stop automatically at a maximum temperature of 50°C.
Study NCT05098171 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Signal Switch Receptor Modified TIL
Description: Adoptive transfer of 2x10\^8-1x10\^10 autologous signal switch receptor modified TILs to patients i.v. in 30-120 minutes.
Study NCT05056038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Quadratus Lumborum block
Description: Local anesthetic may spread to the T6-L1 spinal nerves and paravertebral area by spreading through the lateral QLB to the transversus abdominis plane, and posteriorly via the anterior thoracolumbar fascia.
Study NCT05056038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Quadratus Lumborum Block
Description: In posterior QLB, the local anesthetic can spread on the anterior and lateral cutaneous branches of T4-L1 spinal nerves by administration of the agent to the lateral interfascial triangle.
Study NCT06363903 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mesh allergy test
Description: a 5 mm\^2 part of polypropylene mesh will be dissolved in 1 mL Methyl ethyl ketone (MEK), 25 microliters of this solution will be topically applied in a Finn chamber, and a reaction to the topical applicant will be assessed within 48 hours after application.
Study NCT06363903 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood tests
Description: Blood tests for diagnosis of autoimmune diseases will be performed
Study NCT05339750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-based smartphone application
Description: AI-based smartphone application to record and interpret the patch test results
Study NCT05339750 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Allergen patch
Description: Allergens applied to a patch which is placed on the skin on the forearm region. The patch contains 10 dime-sized disks which contain a different allergen.
Study NCT04783779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant of STARgraft-2 shunt in the upper arm and subsequent use for hemodialysis access
Description: After healing from the surgical procedure the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.
Study NCT05960331 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autonomy supported learning
Description: The ability of learners to participate in determining their own behaviour, which is the feedback schedule regarding their practice performance in this study.
Study NCT05960331 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Practice with predetermined feedback
Description: Learners practice the motor task, while the feedback is provided according to their counterpartner
Study NCT04723641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: functional training exercises
Description: progressive resistive functional strength training from plantigrade foot position conducted for one hour, 3 days/week. The therapist will replace the conventional physical therapy with the progressive resistive functional strength training, when this is consistent with the objectives of the strength training.
Study NCT06188650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: After receiving DEB-BACE treatment, the enrolled patients will rest for one week and then undergo one cycle of treatment with the combination of Anlotinib and Adebelimumab. After one course of treatment, the efficacy will be re evaluated, such as CR, and the treatment with Anlotinib and Adebelimumab will continue; For PR, SD, or PD, continue to receive DEB-BACE combined with anlotinib and adebelimumab as needed, with a maximum of 4 DEB-BACE treatments, followed by continued treatment with anlotinib and adebelimumab
Study NCT06363903 — intervention group
Intervention type: PROCEDURE
Intervention: Mesh removal
Description: If wish for mesh removal persists, this procedure can be performed after separate informed consent (within the study), as standard practice of care.
Study NCT05550402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.
Study NCT05550402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium Bromide
Description: Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.
Study NCT05550402 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol plus Ipratropium Bromide
Description: Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium arm)